依托咪酯镇静与丙泊酚镇静在低风险患者ERCP中的疗效与安全性:双盲随机非劣效性试验
本研究为单中心、随机、双盲、非劣效性试验,纳入ASA I-II级拟行ERCP的患者,比较依托咪酯与丙泊酚镇静的疗效与安全性。主要终点为总体呼吸事件,非劣效界值设为10%。依托咪酯组呼吸事件发生率15.6%,丙泊酚组25.4%,率差-9.8%(单侧97.5%CI,-∞至4.2%),达到非劣效。依托咪酯组心动过速更常见(64.1% vs 34.9%,P=0.001)。
要点
- 依托咪酯镇静在ERCP中总体呼吸事件发生率非劣效于丙泊酚。
- 依托咪酯组心动过速发生率显著高于丙泊酚组(64.1% vs 34.9%,P=0.001)。
- 依托咪酯组一过性低血压有低于丙泊酚组的趋势(6.3% vs 15.9%,P=0.084)。
核心结论
- 在ASA I-II级患者ERCP中,依托咪酯镇静的总体呼吸事件发生率非劣效于丙泊酚镇静。
研究设计与样本
- 单中心、随机、双盲、非劣效性试验,纳入ASA I-II级拟行ERCP的患者,依托咪酯组63例,丙泊酚组64例;所有患者先静脉给予0.05 mg/kg咪达唑仑预处理。
主要发现
- 依托咪酯组呼吸事件10例(15.6%),丙泊酚组16例(25.4%),率差-9.8%(单侧97.5%CI,-∞至4.2%)。
- 心血管事件总发生率依托咪酯组67.2% vs 丙泊酚组50.8%(P=0.060)。
- 心动过速(心率>100次/分)依托咪酯组64.1% vs 丙泊酚组34.9%(P=0.001)。
- 一过性低血压依托咪酯组6.3% vs 丙泊酚组15.9%(P=0.084)。
关键数值与推荐
- 主要终点为总体呼吸事件,非劣效界值为10%。
- 依托咪酯组呼吸事件率15.6%,丙泊酚组25.4%,率差-9.8%(单侧97.5%CI,-∞至4.2%),达到非劣效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Etomidate is a short-acting intravenous hypnotic with a safety profile that is superior to alternative drugs such as propofol. However, there is a lack of evidence on the safety of etomidate in ERCP. The objective of this study was to compare efficacy and safety profiles of etomidate and propofol for endoscopic sedation. METHODS: This single-center, randomized, double-blind, noninferiority trial included patients with American Society of Anesthesiologists (ASA) physical status I to II who had been scheduled for ERCP. All patients received .05 mg/kg midazolam intravenously as pretreatment before receiving etomidate or propofol. Either etomidate or propofol was then administered according to group allocation. The primary endpoint was an overall respiratory event. A noninferiority margin of 10% was assumed. RESULTS: Sixty-three and 64 patients were enrolled in the etomidate and propofol groups, respectively. Respiratory events were identified in 10 patients (15.6%) in the etomidate group and 16 patients (25.4%) on the propofol group, with a rate difference of -9.8% (1-sided 97.5% confidence interval, -∞ to 4.2%). The overall incidence of cardiovascular events tended to be higher in the etomidate group (67.2% vs 50.8%, P = .060). In particular, tachycardia (heart rate > 100 beats/min) was more common in the etomidate group than in the propofol group (64.1% vs 34.9%, P = .001). Transient hypotension tended to be less common in the etomidate group (6.3 vs 15.9%, P = .084). CONCLUSIONS: Etomidate-based sedation during ERCP was noninferior to propofol-based sedation in terms of the overall incidence of respiratory events in patients with ASA physical status I to II. (International Clinical Trials Registry Platform number: KCT0001926.).
引用
- Park CH, Park SW, Hyun B, et al. Efficacy and safety of etomidate-based sedation compared with propofol-based sedation during ERCP in low-risk patients: a double-blind, randomized, noninferiority trial. Gastrointest Endosc. 2017. PMID: 28610897. doi:10.1016/j.gie.2017.05.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。